Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost.
BACKGROUND
In this study we compared the clinical efficiency, safety, and economic benefit of low-dose aprotinin with epsilon aminocaproic acid (EACA) in reducing bleeding after cardiopulmonary bypass operation.


METHODS
In a double-blind, randomized study, 100 patients received low-dose aprotinin (2 x 10(6) kallikrein inhibitor units) or EACA (20 g). The surgical procedure was single- or double-valve replacement with or without coronary artery bypass grafts.


RESULTS
Mediastinal chest drainage and transfusion requirements with both therapies were similar. There were no urgent reoperations to secure hemostasis in either group. Similar levels of D-dimer with both therapies indicate a similar inhibition of fibrinolysis. Release of troponin I was less in the low-dose aprotinin group 1 and 4 hours after bypass, although electrocardiographic measurements did not reflect this difference. Levels of S-100beta and neuron-specific enolase were similar with both therapies, confirming that there was no difference in the occurrence of any adverse neurologic events in either group.


CONCLUSIONS
Low-dose aprotinin and EACA showed similar effects on the reduction of intraoperative and postoperative bleeding. The lower cost of EACA with no change in safety outcome suggests it is the preferred treatment.
Ray
M J
MJ
Department of Haematology, Queensland Health Pathology Service, The Prince Charles Hospital, Brisbane, Australia. raymj@health.qld.gov.au
O'Brien
M F
MF
D015119:Aminocaproic Acid / Q000191:economics / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D007611:Aprotinin / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage* / Q000191:economics
D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D015842:Serine Proteinase Inhibitors; C036309:fibrin fragment D; D007611:Aprotinin; D015119:Aminocaproic Acid